230 related articles for article (PubMed ID: 34768018)
1. How to interpret viral markers in the management of chronic hepatitis B infection.
Riveiro-Barciela M; Pericàs JM; Buti M
Clin Microbiol Infect; 2022 Mar; 28(3):355-361. PubMed ID: 34768018
[TBL] [Abstract][Full Text] [Related]
2. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
Wu JW; Kao JH; Tseng TC
Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
[TBL] [Abstract][Full Text] [Related]
3. New viral biomarkers for Hepatitis B: Are we able to change practice?
Höner Zu Siederdissen C; Maasoumy B; Cornberg M
J Viral Hepat; 2018 Nov; 25(11):1226-1235. PubMed ID: 30187603
[TBL] [Abstract][Full Text] [Related]
4. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
5. Update on hepatitis B virus infection.
You CR; Lee SW; Jang JW; Yoon SK
World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
[TBL] [Abstract][Full Text] [Related]
6. The role of different viral biomarkers on the management of chronic hepatitis B.
Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Apr; 29(2):263-276. PubMed ID: 36655304
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
8. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
9. What is new on HBsAg and other diagnostic markers in HBV infection?
Höner Zu Siederdissen C; Maasoumy B; Cornberg M
Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):281-289. PubMed ID: 28774410
[TBL] [Abstract][Full Text] [Related]
10. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B.
Jeng WJ; Papatheodoridis GV; Lok ASF
Lancet; 2023 Mar; 401(10381):1039-1052. PubMed ID: 36774930
[TBL] [Abstract][Full Text] [Related]
12. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
13. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
[TBL] [Abstract][Full Text] [Related]
14. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
15. [Research progress of biomarkers of hepatitis B virus and clinical significance].
Wang X; Tang X; Han N; Tang H
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Dec; 40(6):1242-1248. PubMed ID: 38151949
[TBL] [Abstract][Full Text] [Related]
16. [New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
Cho YK; Song BC
Korean J Gastroenterol; 2011 Mar; 57(3):144-9. PubMed ID: 21519161
[TBL] [Abstract][Full Text] [Related]
17. The Role of Hepatitis B Core-Related Antigen.
Inoue T; Tanaka Y
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31075974
[TBL] [Abstract][Full Text] [Related]
18. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.
Moini M; Fung S
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458387
[TBL] [Abstract][Full Text] [Related]
19. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
[TBL] [Abstract][Full Text] [Related]
20. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
